The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder

Abstract

Objective Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. Methods A systematic review was conducted to identify contemporary clinical trials of serotonergic psychedelics for the treatment of major depressive disorder and cancer-related depression. Studies published between January 1990 and July 2021 were identified using combinations of search terms, inspection of bibliographies and review of other psychedelic reviews and consensus statements. The levels of evidence for efficacy were graded according to the Canadian Network for Mood and Anxiety Treatments criteria. Results Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). Small randomized controlled trials of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator (escitalopram with supportive psychotherapy) in major depressive disorder, with additional randomized controlled trials showing efficacy specifically in cancer-related depression (Level 3 evidence). There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). Small sample sizes and functional unblinding were major limitations in all studies. Adverse events associated with psychedelics, including psychological (e.g., psychotomimetic effects) and physical (e.g., nausea, emesis and headaches) effects, were generally transient. Conclusions There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder. In Canada, as of 2022, psilocybin remains an experimental option that is only available through clinical trials or the special access program. As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.

Advances in respiratory physiology in mouse models of experimental asthma

“…Other asthmatic phenotypes, such as obesity-associated asthma, can result in restrictive lung physiology as breathing at low lung tidal volumes increases AHR, where actin-myosin cross-linking in ASM may contribute to resistance from muscle stiffening ( Fredberg et al, 1997 ). Neurological and psychological factors have also been linked to asthma presentation ( Rosenblat et al, 2022 ).…”

Bibliometric and visual analysis of the global treatment of affective disorders in the 21st Century: Developments, hotspots, and trends

“…Many studies hypothesized that (Machado et al, 2018) the increase in mortality caused by non-psychiatric diseases may be related to such factors as psychological reactions to diseases, unhealthy behaviors (such as malnutrition or drug abuse), pathophysiological abnormalities of MDD, and poor treatment compliance. McIntyre RS et al pointed out that affective disorders with non-psychiatric comorbidities are related to more severe psychiatric symptoms, more excellent treatment resistance, lower recovery rate, and worse course of disease (Rosenblat et al, 2022). Therefore, the international guidelines on affective disorders emphasize the need to consider the nonpsychiatric complications in affective disorders and call for early detection and better screening strategies.…”

The economics of psychedelic-assisted therapies: A research agenda

“…Some of this evidence indicates that new psychedelic-assisted therapies may be effective not only in managing serious psychiatric conditions, but often in inducing long term remission. Despite these generally encouraging findings, no psychedelic-assisted therapy has yet been adopted into national guidelines; see for example the Canadian Network for Mood and Anxiety Treatments Task Force recommendations ( 37 ). Nor have any previously illegal psychedelic drugs been approved by a relevant regulatory agency as a legal medicine.…”